✦ LIBER ✦

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours

✍ Scribed by Infante, Jeffrey R.; Papadopoulos, Kyriakos P.; Bendell, Johanna C.; Patnaik, Amita; Burris, Howard A.; Rasco, Drew; Jones, Suzanne F.; Smith, Lon; Cox, Donna S.; Durante, Michael; Bellew, Kevin M.; Park, Joohyun (Jennifer); Le, Ngocdiep T.; Tolcher, Anthony W.

Book ID: 122619168
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 448 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2013.03.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I dose-escalation study of AZD7762

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

✍ Sausville, Edward; LoRusso, Patricia; Carducci, Michael; Carter, Judith; Quinn, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 560 KB

494 A phase I trial of SCH900776, a sele

494 A phase I trial of SCH900776, a selective inhibitor of checkpoint kinase CHK-1, in combination with Gemcitabine in advanced solid tumors

✍ A. Daud; C. Soon; G. Springett; D. Mendelson; P. Munster; J. Goldman; J. Strosbe 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase I study of PKC412, a protein kinas

Phase I study of PKC412, a protein kinase C inhibitor, in combination with gemcitabine and cisplatin: Preliminary report of an ongoing phase I study

✍ Monnerat, C; Henriksson, R; Raymond, E; Berthaud, P; Vicente-Azevedo, J; Laveniu 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 106 KB

A phase I schedule dependency study of t

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

✍ Raymond, E.; Alexandre, J.; Faivre, S.; Goldwasser, F.; Besse-Hammer, T.; Gianel 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 270 KB

36 ORAL A Phase I single dose escalation

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Tat 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Phase I Study of Rigosertib, an Inhibito

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

✍ Ma, W. W.; Messersmith, W. A.; Dy, G. K.; Weekes, C. D.; Whitworth, A.; Ren, C.; 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 440 KB